AIZ EBP2a les 1 en 2 by Anna Hoogenkamp https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz HvA HBO-V en-us 2017-04-19 06:14:27 UTC 2026-01-30 14:57:17 UTC hello@padlet.com Deel 1 anna_efj_hoogenkamp https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz/wish/166931786 Vat de baseline kenmerken samen
Wat valt op?
]]> 2017-04-19 06:17:16 UTC https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz/wish/166931786 Deel2a anna_efj_hoogenkamp https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz/wish/166931823 •Randomisation
•1. What information can be found about the way the participants were allocated to the experimental group or the control group for the intervention? 
•a. Was the allocation of the patients to the experimental group and the control group randomised? 
•b. The allocation of the patients to the experimental and the control group should be concealed to the person performing the randomisation. Is this true in this study? 
 
]]> 2017-04-19 06:17:36 UTC https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz/wish/166931823 Deel 2b anna_efj_hoogenkamp https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz/wish/166931879 •Blinding
•2a. Were the patients aware of the group they were treated in (experimental or control group)? 
•2b. Were the clinicians aware of the group allocation? 
•2c. Were the outcome assessors aware of group allocation?
]]> 2017-04-19 06:18:16 UTC https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz/wish/166931879 Cochrane vraag 6,7,8 anna_efj_hoogenkamp https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz/wish/166931915 http://netherlands.cochrane.org/beoordelingsformulieren-en-andere-downloads

]]> 2017-04-19 06:18:41 UTC https://padlet.com/anna_efj_hoogenkamp/lhybcqdmirgz/wish/166931915